Abstract
ObjectivesFolate receptor-alpha (FRα) expression is associated with poor prognosis in endometrial cancer (EC). Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC) comprising a FRα-binding antibody, cleavable linker, and the tubulin-disrupting...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have